SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a subsidiary of Roche Holding AG
(RHHBY), Friday announced a new 5-year data confirming benefit of Evrysdi for
the children with Type 1 spinal muscular atrophy or SMA as they were able to
sit, stand and walk.

SMA is a progressive neuromuscular disease that affects the functioning of nerve
cells, affecting the patient's ability to walk, eat or breathe.

By the end of the Firefish study, 91 percent of children treated with Evrysdi
were alive, 81 percent were alive without permanent ventilation and the majority
were able to sit without support for at least 30 seconds, the company stated.

Also, 96 percent of patients were able to swallow, and 80 percent were able to
feed without the help of a feeding tube by the end of 5 years.

Currently, Genentech's stock is trading at $33.92, up 1.31 percent on the OTC
Markets.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX